Pediatric Infectious Disease

Register      Login

VOLUME 1 , ISSUE 1 ( January-March, 2019 ) > List of Articles


Diagnosis of Childhood Tuberculosis

Abhay K Shah, Aashay A Shah

Keywords : Cartridge-based nucleic acid amplification test, Childhood tuberculosis, Diagnosis

Citation Information : Shah AK, Shah AA. Diagnosis of Childhood Tuberculosis. Pediatr Inf Dis 2019; 1 (1):7-16.

DOI: 10.5005/jp-journals-10081-1103

License: CC BY-NC 4.0

Published Online: 01-03-2019

Copyright Statement:  Copyright © 2019; Jaypee Brothers Medical Publishers (P) Ltd.


Tuberculosis (TB) in India accounts for about a quarter of the world\'s TB cases and children are at high risk of tuberculous infection and TB disease. TB diagnosis in children continues to be a challenge due to difficulty in getting appropriate samples and paucibacillary disease. In recently revised recommendations a major emphasis has been made on microbial diagnosis and more liberal use of molecular diagnostic modalities like cartridge-based nucleic acid amplification test (CBNAAT) and line probe assay. Cartridge based nucleic acid amplification test (CB-NAAT, GeneXpert,) is now considered as a World Health Organization (WHO)-recommended rapid diagnostic (WRD) and is a very simple test, with a well-established role in the diagnosis of pulmonary tuberculosis (PTB) and extrapulmonary tuberculosis (EPTB) cases in comparison to AFB smear. CBNAAT should be offered upfront whereever TB is suspected. Drug sensitivity tests (DST) should always be attempted in all positive cases. For latent TB infection diagnosis intradermal TST is widely used however interferon-gamma release assays is also an equivalent option.

PDF Share
  1. TB Disease Burden & Surveillance in India.
  2. RNTCP Implementation Status Ch4 India TB report
  3. Recent Changes in Tuberculosis Guidelines for Children. Anirban Mandal, Amitabh Singh. Mandal et al., Mycobact Dis 2017, 7:2 DOI: 10.4172/2161-1068.1000237
  4. Testing & diagnosis of TB in India - CB-NAAT, Smear, CXR
  5. Procedures for obtaining clinical samples for smear microscopy Annex 4 Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children. 2nd edition. Geneva: World Health Organization; 2014.ISBN-13: 978-92-4-154874-8
  6. Zar HJ, Hanslo D, Apolles P, et al. Induced sputum versus Induced sputum versus gastric lavage formicrobiological confirmation of pulmonary tuberculosis in infants and young children: a prospective study Lancet 2005;365:130-134
  7. Steingart KR, Ramsay A, Pai M Optimizing sputum smear microscopy for the diagnosis of pulmonary tuberculosis. Expert Rev Anti Infect Ther. 2007 Jun;5(3):327-331
  8. Stop TB Partnership Childhood TB Subgroup. Chapter 1: introduction and diagnosis of tuberculosis in children. Int J Tuberc Lung Dis 2006; 10:1091–1097. [PubMed]
  9. Gonzalez-Angulo Y, Wiysonge CS, Geldenhuys H, et al. Sputum induction for the diagnosis of pulmonary tuberculosis: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis 2012; 31:1619-1630. [PubMed]
  10. Gowda NC, Ray A, Soneja M, et al. Evaluation of Xpert® Mycobacterium tuberculosis/rifampin in sputum-smear negative and sputumscarce patients with pulmonary tuberculosis using bronchoalveolar lavage fluid. Lung India [serial online] 2018 [cited 2019 Mar 4];35:295-300. Available from:
  11. Yon Ju Ryu Diagnosis of Pulmonary Tuberculosis: Recent Advances and Diagnostic Algorithms Tuberc Respir Dis (Seoul). 2015;78(2):64-71. Published online 2015 Apr 2.
  12. Steingart KR, Henry M, Ng V, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006;6:570-581.
  13. WHO, Country TB profile, 2011
  14. World Health Organization. Fluorescent light emitting diode (LED) microscopy for diagnosis of tuberculosis: policy statement [Internet] Geneva: World Health Organization; 2010. [cited 2015 Mar 1]. Available from:
  15. Steingart KR, Ng V, Henry MC, et al. Sputum processing methods to improve the sensitivity and yield of smear microscopy for tuberculosis: a systematic review (unpublished report). Geneva: Special Programme for Research & Training in Tropical Diseases (TDR), World Health Organization, and Foundation for Innovative New Diagnostics (FIND). 2005.
  16. Toman K. How many bacilli are present in a sputum specimen found positive by smear microscopy? In: Frieden TR, ed. Toman's tuberculosis. Case detection, treatment and monitoring, 2nd Edition. Geneva: World Health Organization; 2004. 11-13.
  17. Toman K. How reliable is smear microscopy? In: Frieden TR, ed. Toman's tuberculosis. Case detection, treatment and monitoring, 2nd Edition. Geneva: World Health Organization; 2004:14-22.
  18. World Health Organization. Early detection of tuberculosis: an overview of approaches, guidelines and tools [Internet] Geneva: World Health Organization; 2011. [cited 2015 Mar 1]. Available from:
  19. Essawy TS, Saeed AM, Fouad NA. Comparative study between using lowensteinjensen, Bio-FM media and mycobacteria growth indicator tube (MGIT) system in identification of Mycobacterium tuberculosis. Egypt J Chest Dis Tuberc 2014;63:377-384
  20. Pfyffer GE, Welscher HM, Kissling P, et al. Comparison of the mycobacteria growth indicator tube (mgit) with radiometric and solid culture for recovery of acid-fast bacilli. Journal of Clinical Microbiology 0095-1137/97/$04.0010.
  21. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva: World Health Organization; 2014.
  22. Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampicin resistance by use of ondemand, nearpatient technology. J Clin Microbiol 2010;48(1):229-237.
  23. I Shah, Y GuptaXpert MTB/RIF for diagnosis of tuberculosis and drug resistance in indian children. Indian Pediatr 2016;53:837-838
  24. World health Organisation (WHO). Xpert MTB/RIF implementation manual. Technical and operational ‘how-to’: Practical Considerations. 2014
  25. World health Organisation (WHO). Prevention and management of MDR-TB in children. 2016.
  26. Agrawal M, Bajaj A, Bhatia V, et al. Comparative study of Gene Xpert with ZN stain and culture in samples of suspected pulmonary tuberculosis J Clin Diagn Res 2016;10(5): DC09-DC12
  27. Steingart KR, Sohn H, Schiller I, et al. Xpert (R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults (Review). Cochrane Database of Systematic Reviews 2013;1:CD009593.
  28. World Health Organization 2013. Policy update. Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. WHO/HTM/TB/2013.16
  29. Light RW: Update on tuberculous pleural effusion. Respirology 2010; 15:451-458.
  30. World health Organisation (WHO). Prevention and management of MDR-TB in children. 2016.
  31. World health Organisation (WHO). Xpert MTB/RIF implementation manual. Technical and operational ‘how-to’: Practical Considerations. 2014
  32. Non-inferiority analysis of Xpert MTB/RIF Ultra compared to Xpert MTB/RIF WHO Meeting Report of a Technical Expert Consultation: World Health Organization 2017
  33. World Health Organization. The use of molecular line probe assay for the detection of resistance to isoniazid and rifampicin: policy update. 2016. World Health Organization.
  34. World Health Organization. (2016). The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs: policy guidance. World Health Organization.
  35. Nathavitharana RR, Cudahy PG, Schumacher SG, et al. Accuracy of line probe assays for the diagnosis of pulmonary and multidrugresistant tuberculosis: a systematic review and metaanalysis. Eur Respir J 2017;49(1):1601075.
  36. Theron G, et al. 2016. GenoType® MTBDRsl assay for resistance to secondline antituberculosis drugs. Cochrane Database Syst Rev 9:CD010705.
  37. WHO Recommendations on the Use of the Sl-Lpa
  38. The use of loop-mediated isothermal amplification (TB-LAMP) for the diagnosis of pulmonary tuberculosis Policy guidance World Health Organization 2016
  39. WHO pollicy statement Non-Commercial Culture and Drug- Susceptibility Testing Methods For Screening of Patients at Risk of Multi-Drug Resistant Tuberculosis July 2010
  40. WHO. Policy statement 2007: Liquid media for culture and DST
  41. Tuberculosis diagnostics.
  42. RNTCP-IAP Training module on Revised updated Pediatric TB guielines 2019
  43. Abdel-Samea SA, Ismail YM, Fayed SM, et al. Comparative study between using QuantiFERON and tuberculin skin test in diagnosis of Mycobacterium tuberculosis infection. Egyptian Journal of Chest Diseases and Tuberculosis 2013;62(1):137-143.
  44. Berthet FX, Rasmussen PB, Rosenkrands I, et al. A Mycobacterium tuberculosis operon encoding ESAT= 6 and a novel low-molecular-mass culture filtrate protein (CFP-10). Microbiology 1998 ;144(11):3195-3203.
  45. Barnes PF. Diagnosing latent tuberculosis infection: turning glitter to gold, Am. J. Respir. Crit. Care Med 2004;170:5-6.
  46. WHO 2018 guidelines on TB testing
  47. Guidelines on the management of latent tuberculosis infection
  48. Meissner HC. Treatment of asymptomatic (latent) tuberculosis infection in children. http://www.aappublications.orgnews/2018/12/27/idsnapshot122718
  49. Dharmapalan D. Adenosine deaminasoe (ADA)–A review of its diagnostic utility for TB in children Pediatric Infectious Disease, Vol. II- Apr - Sept 2010.Elsivier
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.